At a recent regenerative medicine conference, stem cell entrepreneur Chuck Meeker expressed optimism that the FDA will soon engage with his industry. He predicted a series of FDA roundtables before the end of the year, though the agency did not confirm any such plans. Meeker's comments came at PepMed 2026, a conference focused on peptides and regenerative health businesses.
Peptides and stem cells are both part of regenerative medicine, which aims to trigger the body's natural healing. While compounded peptides have recently gained some FDA attention, commercially available stem cell therapies remain largely unapproved and operate in a grey market. Industry advocates see the FDA's tentative embrace of peptides as an opening to bring stem cells into a regulated framework.
The source reports that stem cell proponents believe this shift could happen under the influence of RFK Jr. and the MAHA movement, which have embraced these therapies. However, the article does not provide direct quotes from RFK Jr. or FDA officials, and the FDA's silence on imminent roundtables leaves the timeline uncertain.